4134results about "Blood disorder" patented technology

The invention discloses an oral care composition containing ampelopsis japonica polysaccharide and application of the oral care composition in inhibiting gingival bleeding. The oral care composition comprises ampelopsis japonica polysaccharide and an orally acceptable carrier, wherein the pH (Potential of Hydrogen) range of the oral care composition is 5.9 to 7.7. The invention also discloses an application of the ampelopsis japonica polysaccharide in the oral care composition for inhibiting gingival bleeding. The invention discloses application of silicon dioxide with a high oil absorption value in an oral care composition for improving the gingival bleeding inhibiting effect of ampelopsis japonica polysaccharide. The combination of the high-oil-absorption-value silicon dioxide and the low-oil-absorption-value silicon dioxide is applied to the oral care composition for improving the gingival bleeding inhibiting effect of the ampelopsis japonica polysaccharide; the invention further discloses application of sorbitol in the oral care composition for improving the effect of inhibiting gingival bleeding by the ampelopsis japonica polysaccharide. The oral care composition has a hemostatic effect and can effectively solve the problem of gingival bleeding.

The invention relates to ultra-small prussian blue nano-particles (T-USPB-C) carrying tirofian, a preparation method of the nano-particles and application of the nano-particles in preparation of drugs for reducing MVO and MIRI. According to the preparation method, the T-USPB-C is prepared by three steps. The T-USPB-C provided by the invention can carry tirofiban, and has catalase and superoxide dismutase simulated nano-enzyme activity. Moreover, the size of the nano-scale drug is required to reach a nano-scale size, and the drug can be efficiently cleared through kidney excretion, so that the potential long-term toxicity problem is minimized. The ultra-small prussian blue nanoparticle carrying the tirofian has an excellent active oxygen scavenging capability. Microvascular perfusion can be rapidly improved through the antithrombotic effect, then the protection effect is continuously achieved through the anti-oxidation and anti-inflammatory mechanism, and microvascular injury and MIRI are effectively prevented.

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to application of bifidobacterium longum subsp. Infantis Y46 in the anti-aging aspect. The bifidobacterium longum subsp. Infantis Y46 is obtained from excrement of infants. Animal experiments prove that living cell thalli (Y46) and thermally inactivated cell thalli (HKY46) obtained by culturing the bifidobacterium longum subsp. Infantis Y46 by using an MRS liquid culture medium containing L-cysteine hydrochloride (0.05%, v / v) can significantly reduce accumulation of lipofuscin in a host, and prolong the healthy life and life of the host. Therefore, the bifidobacterium longum subsp. Infantis Y46 is a promising probiotic and a promising metagen with an anti-aging function.

The invention discloses a cationic lipid compound, a lipid carrier containing the same and application, and belongs to the technical field of gene therapy. The cationic lipid compound disclosed by the invention has a structure as shown in a formula I, or an isomer, a pharmaceutically acceptable salt and a prodrug thereof. The lipid nanoparticles have the advantages of stable nanostructure, uniform size distribution, good biological biocompatibility, high in-vivo and in-vitro mRNA delivery efficiency, selective organ targeting and the like. The cationic lipid reaction operation is simple, the raw materials are cheap and easy to obtain, and the cationic lipid has high safety, is beneficial to industrial production and quality control, and has a good application prospect.

The invention relates to the field of biological medicine, and provides an application of a dihydroorotate dehydrogenase inhibitor in preparation of megakaryocytes, and the dihydroorotate dehydrogenase inhibitor is a compound shown as a formula I, a formula II or a formula III, or a pharmaceutically acceptable salt of the compound. According to the technical scheme, the dihydroorotate dehydrogenase inhibitor can promote hematopoietic stem / progenitor cells to differentiate into megakaryocytes and platelets, the platelet generation amount is increased by about 2 times, and a promising strategy is provided for in-vivo and in-vitro megakaryocyte and platelet generation.

The invention provides double-stranded ribonucleic acid for reducing blood coagulation factor XI expression and a modifier and application of the double-stranded ribonucleic acid. Cell experiment results show that the oligonucleotide duplex can significantly inhibit the expression of the FXI gene, and can be used for developing anticoagulant drugs.

The present invention belongs to the field of biotechnology. Disclosed is a dosage composition of a complement factor B inhibitor. Specifically, the present invention provides a pharmaceutical composition comprising a compound represented by formula I, an isomer thereof, or a pharmaceutically acceptable salt thereof in a unit dosage form, wherein the mass of the compound or the pharmaceutically acceptable salt thereof is 5-1500 mg based on the free base.

Disclosed is a method of treating liver ischemia reperfusion (I / R) injury in a subject. In some aspects, the method comprises providing a subject suffering from liver I / R injury or at risk of suffering liver I / R injury; and administering to the subject one or more heparan sulfate (HS) compounds. In some aspects, the one or more HS compounds comprises about 5 to about 18 saccharide units, optionally about 12 to about 18 saccharide units. In some aspects, the one or more HS compounds comprises about 12 saccharide units.

The present invention relates to a compound for inducing the expression of the anti-aging gene klotho and a preparation method therefor. The compound represented by Chemical Formula 1, according to the present invention, has an excellent effect of increasing the expression level of the klotho gene which is a gene associated with aging, and thus can be useful for a pharmaceutical composition, cosmetic composition or food composition for preventing skin aging, inhibiting cellular senescence or preventing, treating alleviating a vascular aging-induced disease or a renal disease.

The present invention relates to compounds of formula (I) below, or any one of its pharmaceutically acceptable salts: [Formula 1] JPEG2023523788000127.jpg41170 where R 1 is (C1-C6) alkyl group, spiro (C5-C 11 ) bicyclic rings, fused phenyl groups, substituted phenyl groups, R'-L- groups, where L is either a single bond or a (C1-C3) alkanediyl group, and R' is a (C3-C8) cycloalkyl group, a bridged (C6-C 10 ) cycloalkyl group, (C3-C8) heterocycloalkyl group, or (C3-C8) heteroaryl group, or R'-L- group, where L is a (C1-C3) alkanediyl group and R' is an optionally substituted phenyl group, and R 2 represents a hydrogen atom or a (C1-C3) alkyl group. The present invention further relates to compositions comprising the compound of formula (I), as well as methods for preparing the compound and synthetic intermediates thereof. The present invention also relates to the compound for use as a pharmaceutical, in particular for treating and / or preventing cognitive impairment associated with Down's syndrome; Alzheimer's disease; dementia; tauopathies; Parkinson's disease; CDKL5 deficiency disorders; Phelan-McDermid syndrome; autism; type 1 and type 2 diabetes; folate and methionine metabolism disorders; osteoarthritis; Duchenne muscular dystrophy; some cancers; neuroinflammation, anemia, and viral and unicellular infections, and for regulating body temperature.

The present application provides bicyclic urea compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The present invention relates to antibodies that bind AXL. The present invention relates to anti-AXL antibodies, immunoconjugates, compositions, and methods of using such anti-AXL antibodies, immunoconjugates, or compositions to treat cancer.

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.

The invention provides an RNP compound, an electrotransfection composition and a pharmaceutical composition thereof, a CD34 + cell gene editing method using the composition, and a method for obtaining HBG gene target mutation in a CD34 + cell genome.

The invention relates to pharmaceutical compositions comprising an iRNA agent, e.g., double stranded ribonucleic acid (dsRNA) agent and methods of using such compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without inhibitors).

Provided is a compound and so on having aldehyde dehydrogenase 2 (ALDH2) activation effect. A compound, a pharmaceutically acceptable salt of the compound, or a prodrug of the compound or the salt, the compound being represented by the following formula (1):whereinA is a heterocycle,R1 and R2 are each independently hydrogen, an alkyl, an alkenyl, or an alkynyl,R3 is an alkyl, an alkenyl, or an alkynyl, andX1 and X2 are each independently a halogen.

Methods related to inhibiting CLEC-2 and treating venous thrombosis with certain BTK inhibitors and / or pharmaceutically acceptable salts thereof are provided.

Methods for treating patients with wAIHA comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.

The invention relates to an antibody preparation, which comprises an antibody serving as an active ingredient, and also comprises a buffer system, a stabilizer and a surfactant.

The invention relates to an alkenyl-substituted piperidine compound as well as a pharmaceutical composition, a preparation method and application thereof, and particularly provides the alkenyl-substituted piperidine compound as shown in a formula (I) which can be used for preparing medicines, especially medicines for preventing and / or treating complement bypass mediated diseases or symptoms. Each group in the formula (I) is as defined in the specification.

The present invention relates to a CD117 antibody and a delivery vector using same, such as lipid nanoparticles (LNPs). Further provided in the present invention are a method for delivering a bioactive substance to CD117+ cells by using the delivery vector and a method for preparing such a lipid nanoparticle conjugate.

Disclosed are a peptide amide compound composition, a preparation method therefor and medical use thereof. Specifically, the composition contains a compound of formula (I) and pH regulators, and the pH of the solution thereof is 3-5.5. The composition is stable and requires few excipients, and is stable in clinical use. The composition is used for treating or preventing a disease or condition associated with kappa opioid receptors

The present invention relates to engineered liver-specific core promoters, synthetic promoters (which contains the engineered core promoters and enhancers), expression vectors (which contains the synthetic promoter), as well as methods of using the promoter or the expression vector thereof to address the need in the field, including treatment of various genetic diseases or conditions associated with the liver. In some embodiments, the liver-specific promoter includes continuous or discontinuous genome sequences from SERPINA1 genome.

The invention relates to the technical field of traditional Chinese medicine health-care products, and particularly discloses an earthworm protein peptide composition for improving vascular embolism and a preparation method thereof.The earthworm protein peptide composition is prepared from, by weight, 28-34 parts of earthworm protein peptide, 20-26 parts of active pharmaceutical ingredients, 1-5 parts of ginkgo biloba extract, 12-15 parts of corn oligopeptide powder and 4-8 parts of auxiliary materials; lumbricus protein peptide, active pharmaceutical ingredients, ginkgo biloba extract and corn oligopeptide powder are used as raw materials, a solubilizing component is added in the preparation process, the solubilizing component is prepared by mixing functional extract, nattokinase and tween-80 according to a certain proportion, the functional extract is prepared by coating grape seed extract with hydroxypropyl-beta-cyclodextrin, and the solubilizing component is prepared by mixing the functional extract, the nattokinase and the tween-80 according to a certain proportion. Through the synergistic effect of the components, the antithrombotic effect of the earthworm protein peptide composition is synergistically enhanced.

The invention relates to the field of biological medicines, in particular to application of an SR604 injection to preparation of a medicine for preventing and / or treating hemorrhagic diseases. The SR604 injection provided by the invention contains an SR604 antibody, and the injection dosage of the SR604 antibody in the SR604 injection is selected from 0.025 mg / kg to 0.8 mg / kg. The injection provided by the invention can be used for preventing and / or treating hemorrhagic diseases, the number of hemorrhagic events and the annual hemorrhagic rate of a patient are remarkably reduced by controlling the injection dosage and the injection frequency, and the injection has a relatively good treatment effect on hemophilia A, hemophilia B and congenital blood coagulation factor VII deficiency.

The invention belongs to the technical field of microorganisms and biological medicines, and particularly relates to a postbiotic preparation for improving vascular elasticity and relieving hypertension and thrombus as well as a preparation method and application of the postbiotic preparation. Specifically, a strain of lactobacillus rhamnosus is obtained through screening, a postbiotic preparation is successfully developed based on the strain, and tests prove that the lactobacillus rhamnosus has the effects of reducing inflammatory response of vascular endothelium and reducing oxidative stress level so as to promote repair and regeneration of vascular endothelial cells, improve vascular elasticity and quickly improve hypertension; the anti-thrombus effect can be realized. Meanwhile, by optimizing the condition parameters of the preparation process of the metabolite preparation and combining anaerobic fermentation and aerobic fermentation on the lactobacillus rhamnosus, the advantage that metabolites are comprehensive and rich is achieved, and the metabolite preparation has good practical application value.

The invention relates to a piperidinedione compound as well as a pharmaceutical composition and application thereof, and particularly provides a piperidinedione compound shown in a formula (I) which can be used for preparing medicines, especially medicines for preventing and / or treating diseases or symptoms caused by or related to lymphocyte development or activity disorder. Each group in the formula (I) is as defined in the specification.